



## Helicobacter pylori: Antibiotic Resistance and Treatment

Guest Editors:

**Dr. Ilaria Maria Saracino**

Department of Experimental,  
Diagnostic and Specialty  
Medicine, School of  
Specialization in Microbiology  
and Virology, University of  
Bologna, 40138 Bologna, Italy

**Dr. Matteo Pavoni**

Department of Surgical and  
Medical Sciences, University of  
Bologna, 40138 Bologna, Italy

Deadline for manuscript  
submissions:

**closed (31 August 2021)**

### Message from the Guest Editors

Dear Colleagues,

Treatments of *H. pylori* infection have been complicated by the increasing trends in antimicrobial resistance worldwide, primarily due to the overuse/misuse of antibiotics and the consequent selection of resistant clones. The role played by the frequent onset of adverse events during *H. pylori* therapies (that lead to low compliance) should not be underestimated, either.

It is fundamental to carry out periodic assessments of *H. pylori* antibiotic resistance rates and to monitor treatments' efficacy. The development of new diagnostic tools (i.e., molecular methods to detect gene mutations related to antibiotic resistance) is a very interesting field to further explore. Last but not least, integration of probiotics or other co-adjuvants during antibiotic therapy seems to have a positive impact on therapy outcome. This Special Issue seeks manuscripts that improve our understanding of antimicrobial resistance in *H. pylori*. Submissions regarding resistance mechanisms, new methods, and new therapeutic approaches are especially encouraged.

**Keywords:** *H. pylori* infection; antibiotic resistance mechanisms; use of coadjuvants for antibiotic treatments; epidemiology





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi